This is a clinical trial aimed to investigate if a collagen supplement can improve quality of life, appetite and blood sugar in overweight and obese adults aged 18-65. Hypothesis: Consumption of a collagen supplement for 8 days will improve quality of life and improve glycaemic control in comparison with a placebo in individuals overweight or with obesity with a perceived low quality of life. Participants will be asked to: 1. Consume a collagen peptide supplement for a total of 8 days at a time 2. Fill in questionnaires about quality of life, appetite, mood and energy 3. Wear continuous glucose monitors
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
100
5 g of hydrolysed collagen peptide of bovine origin in powdered form. Taken twice daily for 8 days total.
5 g of maltodextrin in powdered form. Taken twice daily for 8 days total.
Metabolic Research Unit (KCL, Waterloo Campus)
London, London, United Kingdom
RECRUITINGQuality of life scores
Quality of life (QoL) scores based on the composite scoring of the 36-item Short Form Survey (SF-36)
Time frame: Baseline and 8 days
Postprandial appetite, hunger, fullness, satiety or desire to eat
Postprandial appetite (hunger, fullness, satiety or desire to eat), energy and mood after consumption of a standardised challenge meal, measured using a digital visual analogue scale (VAS)
Time frame: 15, 30, 60, 120 and 180 minutes post-meal
Mood
Mood measured using the Positive and Negative Affect Schedule Short Form (PANAS-SF) for positive affects (PA), negative affects (NA) and affect balance scores.
Time frame: Baseline and 7 days
Energy and fatigue
Energy and fatigue measured using the Visual Analogue Scale to Evaluate Fatigue Severity (VAS-F) for fatigue, energy and overall scores
Time frame: Baseline and 7 days
Sleep
Sleep measured with the Pittsburgh Sleep Quality Index (PSQI) for Global PSQI score and component scores of sleep quality, latency, duration, efficiency, disturbances and daytime dysfunction.
Time frame: Baseline and 8 days
Glycaemic variability
Glycaemic variability, including overall mean blood glucose, fasting blood glucose, daytime mean blood glucose, daytime glucose variability (CV), % time within range and number of hypoglycaemic events, measured via a continuous glucose monitor (CGM)
Time frame: From baseline to 8 days
Postprandial glucose response
Postprandial glucose response to a standardised breakfast expressed in difference in glucose Cmax, glucose Cmin, glucose Tmax, glucose Tmin and area under the curve, measured using continuous glucose monitor (CGM)
Time frame: Continous monitoring up to 5 hours post-meal
Habitual diet
Habitual diet assessed via the European Prospective Investigation into Cancer and Nutrition (EPIC) food frequency questionnaire (FFQ)
Time frame: Baseline only
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.